✦ LIBER ✦

Economic burden of Parkinson's disease in a developing country: A retrospective cost analysis in Shanghai, China

✍ Scribed by Gang Wang; Qi Cheng; Rui Zheng; Yu-Yan Tan; Xiao-Kang Sun; Hai-Yan Zhou; Xiao-Lai Ye; Ying Wang; Zeng Wang; Bo-Min Sun; Sheng-Di Chen

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 61 KB
Volume: 21
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.20999

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

We investigated economic costs from patients with Parkinson's disease (PD) in Shanghai, China, which could be used as a baseline for future evaluations. Data were collected from 190 patients by interview during 1‐year period. Direct medical care costs averaged approximately Chinese yuan, renminbi (RMB) 4,305 (USD 519, or EUR 410) per year per patient, of which drugs (RMB 2,677) accounted for the major costly component. Nonmedical direct costs were much less than direct health care costs, averaging approximately RMB 3,301 (USD 398, or EUR 314). Costs due to loss of productivity averaged approximately RMB 73 (USD 8.8, or EUR 7.0) per patient per year. Taken together, the overall mean annual cost for PD in our series was approximately RMB 7,679 (USD 925, or EUR 731), and these costs accounted for around half of the mean annual income. Total cost was significantly associated with the disease severity and the frequency of outpatient visits. In addition, levodopa equivalent dose (LED) and the number of drugs being taken were also closely related with the drug cost. The results indicate that the economic burden of Chinese PD patients is heavy. © 2006 Movement Disorder Society

📜 SIMILAR VOLUMES

Cost of Alzheimer's disease in a develop

Cost of Alzheimer's disease in a developing country setting

✍ M. Zencir; N. Kuzu; N. Gördeles Beşer; A. Ergin; B. Çatak; T. Şahiner 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB 👁 1 views

Purpose To evaluate the economic impact of AD in Denizli, Turkey. Design and Methods This observational study was conducted with 42 AD patients and their primary caregivers. During the initial interview, demographic data and medical histories were collected with questionnaires. For an observational

Direct costs of managing Parkinson's dis

Direct costs of managing Parkinson's disease in india: Concerns in a developing country

✍ Mona Ragothaman; Shyla T. Govindappa; Rohini Rattihalli; Dodaballapur K. Subbakr 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

## Abstract Medicines and surgical interventions improve the quality of life of Parkinson's disease (PD) patients. These are still expensive options and are unaffordable to those living in developing countries. Managing PD in Indians who have a low annual gross national income (GNI; US$ 450–540) an

Validity of a modified Parkinson's disea

Validity of a modified Parkinson's disease screening questionnaire in India: Effects of literacy of participants and medical training of screeners and implications for screening efforts in developing countries

✍ Nagaraja Sarangmath; Rohini Rattihalli; Mona Ragothaman; Gururaj Gopalkrishna; S 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB 👁 1 views

## Abstract The prevalence of Parkinson's disease (PD) is low among Indians, except in the Parsis. Data for Indians come from studies using different screening tools and criteria to detect PD. An epidemiological study in India, which has nearly a billion people, more than 18 spoken languages, and v